Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Laboratorios SALVAT has granted Kwang Dong Pharmaceutical an exclusive license to develop, register and market Tarafenacin in South Korea for overactive bladder syndrome (OAB).
Subscribe to our email newsletter
As per the terms of the agreement, Kwang Dong will develop and commercialise Tarafenacin in South Korea.
Additionally, the terms of the agreement include an upfront payment and additional milestone payments by Kwang Dong to SALVAT, and SALVAT will supply the drug to Kwang Dong.
Tarafenacin is a new potent and selective M3 muscarinic antagonist for the treatment of OAB which has completed Phase IIa clinical trials.
SALVAT claimed that in earlier Phase I clinical trials, Tarafenacin was proven to be safe both in healthy young and elderly volunteers, while in the Phase IIa clinical trial in OAB patients, Tarafenacin showed an excellent efficacy and tolerability profile.
SALVAT president Javier Peris said that they were excited about the agreement and were delighted to have Kwang Dong as a partner to develop Tarafenacin.
"We are pleased to establish long-term relations with Kwang Dong and consider this agreement to be a first step in the realisation of SALVAT’s strategy to partner Tarafenacin for advanced development and marketing worldwide," Peris said.
Kwang Dong president Sung Won Choi said that Kwang Dong believe that Tarafenacin has a good potential to succeed in satisfying the unmet therapeutic needs or improving the side effects of OAB.